RMD
RESMED INC
NYSE · Healthcare · Medical - Instruments & Supplies · US
$239.77
+0.33%Year over year
Reported trailing growth
- Revenue
- +9.9%
- EBITDA
- +12.7%
- EBIT
- +12.3%
- EPS
- +9.3%
- Free cash flow
- +74.2%
- Operating cash flow
- +80.2%
Forward estimates
Based on analyst estimates
- Revenue
- +3.9%
- EBITDA
- +13.4%
- EPS
- +19.1%
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- +16.5%
- EBIT
- +19.0%
- Net income
- +19.3%
- EPS
- +19.5%
- Free cash flow
- +43.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026